News Conference News ACC 2025 Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection Michael O'Riordan March 30, 2025
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2021 High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE Michael O'Riordan May 15, 2021
News Conference News ACC 2020 PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years Michael O'Riordan March 30, 2020
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
News Conference News ACC 2018 Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension Michael O'Riordan March 15, 2018